

Jan Delaval

98817

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jennifer Kim Examiner #: 77469 Date: 7/15/03
Art Unit: 1611 Phone Number 30 8-2232 Serial Number: 10/046129
Mail Box and Bldg/Room Location: 2D11 Results Format Preferred (circle): PAPER DISK E-MAIL
2B19

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Treatment of sleep disturbances

Inventors (please provide full names): Koch et al.

Earliest Priority Filing Date: 1/19/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

1) Please search claims 1 - 13

RECEIVED
JUL 15 2003
(SIC)

THY

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher:	<u>Jan</u>	NA Sequence (#)	STN <input checked="" type="checkbox"/>
Searcher Phone #:	<u>4458</u>	AA Sequence (#)	Dialog _____
Searcher Location:		Structure (#)	Questel/Orbit _____
Date Searcher Picked Up:	<u>7/16/03</u>	Bibliographic	<input checked="" type="checkbox"/> Dr.Link _____
Date Completed:	<u>7/16/03</u>	Litigation	Lexis/Nexis _____
Searcher Prep & Review Time:		Fulltext	Sequence Systems _____
Clerical Prep Time:	<u>15</u>	Patent Family	WWW/Internet _____
Online Time:	<u>+45</u>	Other	Other (specify) _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 98817

TO: Jennifer Kim
Location: 2d17 / 2b19
Wednesday, July 16, 2003
Art Unit: 1617
Phone: 308-2232
Serial Number: 10 / 046727

From: Jan Delaval
Location: Biotech-Chem Library
CM1-1E07
Phone: 308-4498
jan.delaval@uspto.gov

Search Notes

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov



STIC SEARCH RESULTS

Biotech-Chem Library

Questions about the scope or the results of the search? Contact **the searcher or contact:**

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* *Example: 1610*
- *Relevant prior art found, search results used as follows:*
- 102 rejection
 - 103 rejection
 - Cited as being of interest.
 - Helped examiner better understand the invention.
 - Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- Foreign Patent(s)
- Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- Results verified the lack of relevant prior art (helped determine patentability).
- Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 - Circ. Desk

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:09:43 QN 16 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Jan Delaval
 Reference Librarian
 Biotechnology & Chemical Library
 Civil 1E07 - 703-308-4498
 jsn.delaval@uspto.gov

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2003 VOL 139 ISS 3
 FILE LAST UPDATED: 15 Jul 2003 (20030715/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 198

L98 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 AN 2003:117637 HCAPLUS
 DN 138:158841
 TI Sucralose formulations to mask unpleasant tastes
 IN Jaeger, David; Dickerson, Jay; Mogavero, Annabelle
 PA Wyeth, John, and Brother Ltd., USA
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-715
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011306	A1	20030213	WO 2002-US24298	20020731
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-308912P P 20010731

AB The present invention is directed to a pharmaceutically acceptable taste masking liq. excipient base for administration of a relatively large amt. of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addn. of sucralose to the excipient base with maintenance of a pH 2-5. The invention is further directed to medicinal compns. comprising such a liq. excipient base and unpleasant tasting medicines. Still further, the invention is directed to a method for taste masking unpleasant tasting medicines through their incorporation into the claimed liq. excipient bases. A

cough syrup , contained guaifenesin 2.00, pseudoephedrine-HCl 0.60, dextromethorphan-HBr 0.20, PEG-1450 20.00, glycerin 6.00, high-fructose corn syrup (55%) 45.00, anhyd. citric acid 1.60, and 70% sorbitol 5.00, sodium citrate 0.20, sodium benzoate 0.30, Red No. 40 dye 0.05, golden punch flavor 0.10, sucralose 0.20, and water to 100.0%.

ST sucralose formulation unpleasant taste masking

IT Anti-inflammatory agents

(nonsteroidal; sucralose formulations to mask unpleasant tastes)

IT Analgesics

Antibiotics

Antihistamines

Antitumor agents

Antitussives

Bitterness

Decongestants

Expectorants

Human

(sucralose formulations to mask unpleasant tastes)

IT Drug delivery systems

(syrups, cough; sucralose formulations to mask unpleasant tastes)

IT 52-26-6, Codeine phosphate 58-73-1, **Diphenhydramine**

59-33-6, Pyrilamine 59-42-7, Phenylephrine 77-22-5, Caramiphen 86-22-6, Brompheniramine 91-81-6, Tripelenamine 93-14-1, Guaifenesin 103-90-2, Acetaminophen 113-92-8, Chlorpheniramine maleate 118-23-0, Bromodiphenhydramine 125-69-9, Dextromethorphan hydrobromide 129-03-3, Cyproheptadine 132-21-8, DexBrompheniramine 345-78-8, Pseudoephedrine hydrochloride 486-12-4, Triprolidine 562-10-7, Doxylamine 569-59-5, Phenindamine 980-71-2, Brompheniramine maleate 1321-14-8, Potassium guaicolsulfonate 1420-53-7, Codeine sulfate 2451-01-6, Terpin hydrate 3964-81-6, Azatadine 7681-11-0, Potassium iodide (KI), biological studies 7778-49-6, Potassium citrate 14838-15-4, Phenylpropanolamine 15687-27-1, **Ibuprofen** 22071-15-4, Ketoprofen 22204-53-1, Naproxen 25523-97-1, DexChlorpheniramine 56038-13-2,

Sucralose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sucralose formulations to mask unpleasant tastes)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Blase; US 5409907 A 1995 HCPLUS

(2) Cherukuri; US 5013716 A 1991 HCPLUS

IT 58-73-1, **Diphenhydramine** 15687-27-1,


Ibuprofen

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sucralose formulations to mask unpleasant tastes)


RN 58-73-1 HCPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 15687-27-1 HCPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:555345 HCAPLUS

DN 137:103930

TI **Ibuprofen-diphenhydramine** composition and method for the treatment of pain-associated **sleep** disturbances

IN Cooper, Stephen Allen; Doyle, Geraldine Ann; Cook, Graham David; Koch, Todd Shawn; Fort, James Joseph; Bianco, Giustino; Giamalva, David Hugh

PA Wyeth, John, and Brother Ltd., USA

SC PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002056877	A1	20020725	WO 2002-US3855	20020118	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 2002177626	A1	20021128	US 2002-46727	20020117	<--
PRAI	US 2001-262387P	P	20010119			<--
AB	The invention provides a compn. for treating pain-assocd. sleep disturbances, esp. shortened sleep duration, comprising ibuprofen and diphenhydramine . The compn. is further prep'd. as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule compn., to prevent interaction between the active ingredients.					
ST	ibuprofen diphenhydramine pharmaceutical pain assocd sleep disturbance treatment					
IT	Drug delivery systems (caplets, bilayer; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Drug delivery systems (capsules; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Sleep (disorder; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)					
IT	Analgesics Drug delivery systems Drug interactions Human					

Pain

(ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

IT Polyoxalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

IT Surgery

(oral; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

IT Drug delivery systems

(tablets, bilayer; ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

IT 58-73-1, Diphenhydramine 147-24-0,

Diphenhydramine hydrochloride 15687-27-1,

Ibuprofen 88637-37-0, Diphenhydramine citrate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

IT 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cevc Gregor; EP 0475160 A 1992 HCPLUS

(2) Charles, F; WO 9729735 A 1997 HCPLUS

(3) Drizen, A; US 6063405 A 2000 HCPLUS

(4) Lam Pharmaceuticals Inc; WO 9711681 A 1997 HCPLUS

(5) Sunshine, A; US 4522826 A 1985 HCPLUS

(6) Sunshine, A; US 4985459 A 1991 HCPLUS

IT 58-73-1, Diphenhydramine 147-24-0,

Diphenhydramine hydrochloride 15687-27-1,

Ibuprofen 88637-37-0, Diphenhydramine citrate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ibuprofen-diphenhydramine compn. and method for treatment of pain-assocd. sleep disturbances)

RN 58-73-1 HCPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)

Ph₂CH—O—CH₂—CH₂—NMe₂

RN 147-24-0 HCPLUS


CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Ph₂CH—O—CH₂—CH₂—NMe₂

HCl

RN 15687-27-1 HCPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 88637-37-0 HCPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 77-92-9

CMF C6 H8 O7



CM 2

CRN 58-73-1

CMF C17 H21 N O


Ph₂CH-O-CH₂-CH₂-NMe₂

IT 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ibuprofen-diphenhydramine compn. and method for
treatment of pain-assocd. sleep disturbances)

RN 25322-68-3 HCPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 3 OF 5 HCPLUS COPYRIGHT 2003 ACS

AN 2002:157572 HCPLUS

DN 136:189396

TI Ibuprofen solutions for capsule-filling and
capsule preparations

IN Kato, Soichiro; Tsumori, Katsuyuki; Shinoda, Yasuo; Inagi, Toshio

PA Kowa Company, Ltd., Japan

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

IC ICM A61K031-192

ICS A61K009-08; A61K009-48; A61K047-34; A61K047-10; A61K047-06;
A61K047-08

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015900	A1	20020228	WO 2001-JP7223	20010823 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001080124	A5	20020304	AU 2001-80124	20010823 <--
	EP 1321140	A1	20030625	EP 2001-958434	20010823 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 2000-255827	A	20000825	<--	
	WO 2001-JP7223	W	20010823		

AB Capsule preps. are produced by using solns. for capsule
-filling which contain **ibuprofen**, **polyethylene glycol**, water and terpenes (menthol, limonene, borneol, dl-camphor, mentha oil, etc.) optionally together with one or more drugs selected from among antipyretic analgesics, antihistamines, antitussives, expectorants, sympathetic stimulants, analectics, hypnotic sedatives and anti-inflammatory agents, solubilizers, thickeners, pH controlling agents, colorants, etc. Thus, it is attempted to relieve the bitterness of **ibuprofen** and establish an immediate action at the same time.

ST capsule ibuprofen PEG terpene

IT Antipyretics

(analgesic; capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Analgesics

(antipyretic; capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Anti-inflammatory agents

Antihistamines

Antitussives

Expectorants

Hypnotics and Sedatives

Nervous system stimulants

(capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Polyoxyalkylenes, biological studies

Terpenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Drug delivery systems

(capsules; capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mint, Mentha; capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT Nerve

(sympathetic, stimulants; capsules contg. **ibuprofen** and PEG and terpenes and other drugs)

IT 58-08-2, Caffeine, biological studies 76-22-2, dl-Camphor 89-78-1,
 Menthol 93-14-1, Guaifenesin, 113-92-8, Chlorpheniramine maleate
 125-69-9, Dextromethorphan hydrobromide 138-86-3, Limonene
147-24-0, Diphenhydramine hydrochloride
 507-70-0, Borneol 912-60-7, Noscapine hydrochloride **15687-27-1**
 , Ibuprofen 18760-80-0, dl-Methylephedrine hydrochloride
 24204-13-5, Dihydrocodeine phosphate **25322-68-3**,
Polyethylene glycol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (capsules contg. ibuprofen and PEG and
 terpenes and other drugs)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Consumer Health S A; ZA 9706189 A 1998 HCPLUS
- (2) Consumer Health S A; ZA 9706189 A 1998 HCPLUS
- (3) Consumer Health S A; AU 9734442 A 1998 HCPLUS
- (4) Consumer Health S A; AU 9734442 A 1998 HCPLUS
- (5) Consumer Health S A; WO 9802182 A1 1998 HCPLUS
- (6) Consumer Health S A; WO 9802182 A1 1998 HCPLUS
- (7) R P Scherer Corporation; JP 01502185 A 1988
- (8) R P Scherer Corporation; EP 293406 A1 1988 HCPLUS
- (9) R P Scherer Corporation; US 5071643 1988 HCPLUS
- (10) R P Scherer Corporation; US 5360615 1988 HCPLUS
- (11) R P Scherer Corporation; ZA 8708723 A 1988 HCPLUS
- (12) R P Scherer Corporation; AU 8781573 A 1988 HCPLUS
- (13) R P Scherer Corporation; WO 8802625 A1 1988 HCPLUS
- (14) Taisho Pharmaceutical Co Ltd; JP 08333246 A 1996 HCPLUS
- (15) Taisho Pharmaceutical Co Ltd; US 5827852 A 1996 HCPLUS
- (16) The Procter & Gamble Company; JP 08509725 A 1994
- (17) The Procter & Gamble Company; US 5827852 A 1994 HCPLUS
- (18) The Procter & Gamble Company; EP 695175 A1 1994 HCPLUS
- (19) The Procter & Gamble Company; WO 9425009 A1 1994 HCPLUS
- (20) The Procter & Gamble Company; NO 9504146 A 1994 HCPLUS
- (21) The Procter & Gamble Company; FI 9505144 A 1994 HCPLUS

IT **147-24-0, Diphenhydramine hydrochloride**


15687-27-1, Ibuprofen 25322-68-3,

Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (capsules contg. ibuprofen and PEG and
 terpenes and other drugs)

RN 147-24-0 HCPLUS


CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 15687-27-1 HCPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2003 ACS
 AN 1999:27707 HCAPLUS
 DN 130:86181
 TI Pharmaceutical formulations containing **ibuprofen** and **diphenhydramine** analgesics
 IN Hough, Douglas R.; Nelson, Edward B.; Raffa, Robert B.
 PA McNeil-PPC, USA
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-19
 ICS A61K031-135; A61K031-19; A61K031-135
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858640	A1	19981230	WO 1997-US10857	19970623 <--
				W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9743256	A1	19990104	AU 1997-43256	19970623 <--

PRAI WO 1997-US10857 19970623 <--
 AB Disclosed are compns. comprising **ibuprofen** (I) and **diphenhydramine** (II) and methods for their use in analgesia. When **ibuprofen** and **diphenhydramine** are within certain ratios, their pharmacol. effects are superadditive. ED50 of I and II.HCl decreased from 36.5 and 8.0 mg/kg, resp. to 2.4 mg/kg orally each, when combined and none of the mice tested in acetylcholine bromide induced abdominal constriction assay showed writhing.
 ST pharmaceutical formulation **ibuprofen diphenhydramine synergism analgesic**
 IT Alcohols, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (C16-18; pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)


- IT Quaternary ammonium compounds, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkylbenzyldimethyl, chlorides; pharmaceutical formulations contg.
 ibuprofen and diphenhydramine analgesics)
- IT Polyoxyalkylenes, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkylene derivs.; pharmaceutical formulations contg. ibuprofen
 and diphenhydramine analgesics)
- IT Emulsifying agents
 (anionic; pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)
- IT Fatty acids, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (esters, with polyoxyethylene sorbitan; pharmaceutical
 formulations contg. ibuprofen and diphenhydramine
 analgesics)
- IT Castor oil
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ethoxylated; pharmaceutical formulations contg. ibuprofen
 and diphenhydramine analgesics)
- IT Emulsifying agents
 (nonionic; pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)
- IT Acacia
 Antihistamines
 (pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)
- IT Lanolin
 Lecithins
 Paraffin oils
 Waxes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)
- IT Analgesics
 (synergistic; pharmaceutical formulations contg. ibuprofen
 and diphenhydramine analgesics)
- IT 58-73-1, Diphenhydramine 15687-27-1,
Ibuprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)
- IT 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol,
 biological studies 57-88-5, Cholest-5-en-3-ol (3. β .)-, biological
 studies 102-71-6, Triethanolamine, biological studies 111-42-2,
 biological studies 112-80-1, Oleic acid, biological studies 120-51-4,
 Benzylbenzoate 121-54-0 141-43-5, biological studies 151-21-3,
 Sodium lauryl sulfate, biological studies 577-11-7, Docusate sodium
 7558-79-4 8044-71-1, Cetrimide 9002-89-5 9004-64-2, Hydroxypropyl
 cellulose 9004-67-5, Methylcellulose 9004-99-3,
 Polyoxyethylene stearate 9005-32-7, Alginic acid 9005-63-4D,
 Polyoxyethylene sorbitan, esters with fatty acids 12441-09-7D,
 Sorbitan, esters 12619-70-4, Cyclodextrin 25322-68-3D,
 alkylene derivs. 25496-72-4, Glyceryl monooleate 31566-31-1, Glyceryl
 monostearate 36653-82-4, Cetyl alcohol 106392-12-5, Poloxamer
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations contg. ibuprofen and
 diphenhydramine analgesics)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

(1) Motola, S; US 5024997 A 1991 HCPLUS


(2) Richardson Vicks Inc; US 4522826 1985 HCPLUS
 (3) Richardson Vicks Inc; WO 8503443 A 1985 HCPLUS
 IT 58-73-1, Diphenhydramine 15687-27-1,
Ibuprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
 RN 58-73-1 HCPLUS
 CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 15687-27-1 HCPLUS
 CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX NAME)



IT 25322-68-3D, alkylene derivs.
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations contg. **ibuprofen** and **diphenhydramine** analgesics)
 RN 25322-68-3 HCPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L98 ANSWER 5 OF 5 HCPLUS COPYRIGHT 2003 ACS
 AN 1991:589755 HCPLUS
 DN 115:189755
 TI Pharmaceutical composition and methods for treating the symptoms of overindulgence
 IN Goldman, William J.; Gates, Thomas N.
 PA McNeil-PPC, Inc., USA
 SO Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K031-415
 ICS A61K031-34; A61K031-165; A61K031-19; A61K031-44
 ICI A61K031-415, A61K031-19, A61K031-165; A61K031-34, A61K031-165; A61K031-165, A61K031-135; A61K031-19, A61K031-135; A61K031-44, A61K031-19, A61K031-165
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 426479	A1	19910508	EP 1990-311995	19901101
	EP 426479	B1	19940216		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI				
	IN 171746	A	19921226	IN 1990-CA907	19901029
	CA 2028746	AA	19910503	CA 1990-2028746	19901031
	CA 2028746	C	19951226		
	AU 9065689	A1	19910509	AU 1990-65689	19901031
	AU 646230	B2	19940217		
	ZA 9008775	A	19920729	ZA 1990-8775	19901101
	AT 101515	E	19940315	AT 1990-311995	19901101
	ES 2057439	T3	19941016	ES 1990-311995	19901101
	JP 03206052	A2	19910909	JP 1990-298713	19901102
	US 5204118	A	19930420	US 1992-876824	19920429
	IN 176327	A	19960427	IN 1992-CA757	19921016
	US 5417980	A	19950523	US 1994-268865	19940629
PRAI	US 1989-430837	A	19891102		
	IN 1990-CA907	A1	19901029		
	EP 1990-311995	A	19901101		
	US 1992-876824	A3	19920429		
	US 1993-46534	B1	19930413		
AB	Pharmaceutical compns. which can relieve the symptoms of overindulgence, such as headache and acid indigestion, comprise (1) acetaminophen or a nonsteroidal antiinflammatory drug and (2) histamine H1 or H2 receptor blocker, proton pump inhibitor, or a combination thereof. The compn. can be in the form of tablets, capsules, or liqs. Thus, a tablet contained acetaminophen 500, cimetidine 150 mg, and other auxiliary agents and coloring agents.				
ST	overeating symptom antiinflammatory antihistaminic tablet; acetaminophen cimetidine tablet overeating symptom				
IT	Headache (from overeating, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Inflammation inhibitors (mixts. with antihistaminics, headache and indigestion from overeating treatment with)				
IT	Antacids and Antiflatulents (mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Antihistaminics (H1, mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Antihistaminics (H2, mixts. with inflammation inhibitors, headache and indigestion from overeating treatment with)				
IT	Digestive tract (disease, indigestion, from overeating, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Appetite (disorder, hyperphagia, discomfort from, treatment of, inflammation inhibitor-antihistaminic combinations for)				
IT	Pharmaceutical dosage forms (liqs., oral, of anti-inflammatory and antihistaminic combinations, for treatment of headache and indigestion from overeating)				
IT	Pharmaceutical dosage forms (tablets, of anti-inflammatory and antihistaminic combinations, for treatment of headache and indigestion from overeating)				
IT	53-86-1D, mixts. with antihistaminics 58-73-1D, mixts. with anti-inflammatory agent 59-33-6D, Pyrilamine, mixts. with anti-inflammatory agent 60-87-7D, Promethazine, mixts. with anti-inflammatory agent 61-68-7D, mixts. with antihistaminics 68-88-2D, Hydroxyzine, mixts. with anti-inflammatory agent 79-09-4D,				

Propanoic acid, derivs., mixts. with antihistaminics 82-92-8D,
 Cyclizine, mixts. with anti-inflammatory agent 91-40-7D, Fenamic acid,
 derivs., mixts. with antihistaminics 91-81-6D, Tripelenamine, mixts.
 with anti-inflammatory agent 103-90-2D, Acetaminophen, mixts. with
 antihistaminics 113-92-8D, Chlorpheniramine, mixts. with
 anti-inflammatory agent 486-16-8D, Carbinoxamine, mixts. with
 anti-inflammatory agent 523-87-5D, mixts. with anti-inflammatory agent
 569-65-3D, Meclizine, mixts. with anti-inflammatory agent 644-62-2D,
 mixts. with antihistaminics 15687-27-1D, Ibuprofen, mixts. with
 antihistaminics 22071-15-4D, mixts. with antihistaminics 22204-53-1D,
 mixts. with antihistaminics 26171-23-3D, Tolmetin, mixts. with
 antihistaminics 29679-58-1D, Fenoprofen, mixts. with antihistaminics
 32536-43-9D, Indole acetic acid, derivs., mixts. with antihistaminics
 36322-90-4D, Piroxicam, mixts. with antihistaminics 38194-50-2D,
 Sulindac, mixts. with antihistaminics 51481-61-9D, Cimetidine, mixts.
 with anti-inflammatory agent 66357-35-5D, Ranitidine, mixts. with
 anti-inflammatory agent 73590-58-6D, mixts. with anti-inflammatory agent
 76824-35-6D, mixts. with anti-inflammatory agent 136584-95-7
 136584-96-8 136584-97-9 136584-98-0 136584-99-1 136585-00-7
 136585-01-8 136585-02-9 136585-03-0 136585-04-1 136585-05-2
 136585-06-3 136585-07-4 136585-08-5

RL: BIOL (Biological study)

(headache and indigestion from overeating treatment with)

IT 136585-08-5

RL: BIOL (Biological study)

(headache and indigestion from overeating treatment with)


RN 136585-08-5 HCAPLUS

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, mixt. with
 2-(diphenylmethoxy)-N,N-dimethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 15687-27-1

CMF C13 H18 O2



CM 2

CRN 58-73-1

CMF C17 H21 N O

Ph₂CH—O—CH₂—CH₂—NMe₂

=> sel hit rn 198
 E7 THROUGH E12 ASSIGNED

=> fil reg;s e7-e12

FILE 'REGISTRY' ENTERED AT 17:09:58 ON 16 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2003 HIGHEST RN 548735-19-9
DICTIONARY FILE UPDATES: 15 JUL 2003 HIGHEST RN 548735-19-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


1 15687-27-1/BI
(15687-27-1/RN)
1 25322-68-3/BI
(25322-68-3/RN)
1 58-73-1/BI
(58-73-1/RN)
1 147-24-0/BI
(147-24-0/RN)
1 136585-08-5/BI
(136585-08-5/RN)
1 88637-37-0/BI
(88637-37-0/RN)
L99 6 (15687-27-1/BI OR 25322-68-3/BI OR 58-73-1/BI OR 147-24-0/BI OR
136585-08-5/BI OR 88637-37-0/BI)

=> d ide can tot

L99 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 136585-08-5 REGISTRY
CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, mixt. with
2-(diphenylmethoxy)-N,N-dimethylethanamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, mixt. contg. (9CI)
MF C17 H21 N O . C13 H18 O2
CI MXS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 15687-27-1
CMF C13 H18 O2



CM 2

CRN 58-73-1
CMF C17 H21 N OPh₂CH—O—CH₂—CH₂—NMe₂1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 115:189755

L99 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 88637-37-0 REGISTRY
CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Diphenhydramine citrate
MF C17 H21 N O . C6 H8 O7
CI COM
SR Commission of European Communities
LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN,
IPA, PROMT, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 77-92-9
CMF C6 H8 O7

CM 2

CRN 58-73-1
CMF C17 H21 N OPh₂CH—O—CH₂—CH₂—NMe₂

15 REFERENCES IN FILE CA (1957 TO DATE)
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:103930

REFERENCE 2: 137:11003

REFERENCE 3: 135:262242

REFERENCE 4: 132:255811

REFERENCE 5: 129:265468

REFERENCE 6: 129:127191

REFERENCE 7: 127:55916

REFERENCE 8: 124:298541

REFERENCE 9: 121:42500

REFERENCE 10: 120:307174

L99 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 25322-68-3 REGISTRY

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .alpha.,.omega.-Hydroxypoly(ethylene oxide)

CN .alpha.-Hydro-.omega.-hydroxypoly(oxy-1,2-ethanediyl)

CN .alpha.-Hydro-.omega.-hydroxypoly(oxyethylene)

CN 1,2-Ethanediol, homopolymer

CN 16600

CN 1660S

CN 400DAB8

CN Alkox

CN Alkox E 100

CN Alkox E 130

CN Alkox E 160

CN Alkox E 240

CN Alkox E 30

CN Alkox E 45

CN Alkox E 60

CN Alkox E 75

CN Alkox R 1000

CN Alkox R 15

CN Alkox R 150

CN Alkox R 400

CN Alkox SR

CN Antarox E 4000

CN Aquacide III

CN Aquaffin

CN Badimol

CN BDH 301

CN Bradsyn PEG

CN Breox 2000

CN Breox 20M

CN Breox 4000

CN Breox 550

CN Breox PEG 300

CN CAFO 154

CN Carbowax

CN Carbowax 100

CN Carbowax 1000
 CN Carbowax 1350
 CN Carbowax 14000
 CN Carbowax 1500
 CN Carbowax 1540
 CN Carbowax 20
 CN Carbowax 200
 CN Carbowax 20000
 CN Carbowax 25000
 CN Carbowax 300
 CN Carbowax 3350
 CN Carbowax 400
 CN Carbowax 4000
 CN Carbowax 4500
 CN Carbowax 4600

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

AR 9002-90-8

DR 12676-74-3, 12770-93-3, 9081-95-2, 9085-02-3, 9085-03-4, 54510-95-1,
 125223-68-9, 54847-64-2, 59763-40-5, 64441-68-5, 64640-28-4, 133573-31-6,
 25104-58-9, 25609-81-8, 134919-43-0, 101677-86-5, 99264-61-6, 106186-24-7,
 112895-21-3, 114323-93-2, 50809-04-6, 50809-59-1, 119219-06-6, 60894-12-4,
 61840-14-0, 37361-15-2, 112384-37-9, 70926-57-7, 75285-02-8, 75285-03-9,
 77986-38-0, 150872-82-5, 154394-38-4, 79964-26-4, 80341-53-3, 85399-22-0,
 85945-29-5, 88747-22-2, 34802-42-1, 107502-63-6, 107529-96-4, 116549-90-7,
 156948-19-5, 169046-53-1, 188364-77-4, 188924-03-0, 189154-62-9,
 191743-71-2, 201163-43-1, 206357-86-0, 221638-71-7, 225502-44-3,
 270910-26-4, 307928-07-0, 356055-70-4, 391229-98-4

MF (C₂H₄O)_nH₂O

CI PMS, COM


PCT Polyether

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABAB, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
 DIOGENES, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2,
 HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
 PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN,
 USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



69890 REFERENCES IN FILE CA (1957 TO DATE)

17762 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

70151 REFERENCES IN FILE CAPLUS (1957 TO DATE)

- REFERENCE 1: 139:46031
 REFERENCE 2: 139:45038
 REFERENCE 3: 139:44671
 REFERENCE 4: 139:44654
 REFERENCE 5: 139:44568
 REFERENCE 6: 139:44208

REFERENCE 7: 139:43981

REFERENCE 8: 139:43290

REFERENCE 9: 139:43265

REFERENCE 10: 139:42605

L99 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 15687-27-1 REGISTRY

CN Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN (.+-.)-.alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid

CN (.+-.)-2-(p-Isobutylphenyl)propionic acid

CN (.+-.)-Ibuprofen

CN (.+-.)-Ibuprophen

CN (4-Isobutylphenyl)-.alpha.-methylacetic acid

CN (RS)-Ibuprofen

CN (S)-4-Isobutyl-.alpha.-methylphenylacetic acid

CN .alpha.- (4-Isobutylphenyl)propionic acid

CN .alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid

CN 2-(4'-Isobutylphenyl)propionic acid

CN 2-(4-Isobutylphenyl)propanoic acid

CN 2-(p-Isobutylphenyl)propionic acid

CN 4-Isobutyl-.alpha.-methylphenylacetic acid

CN 4-Isobutylhydratropic acid

CN Act 3

CN Adex 200

CN Adran

CN Advil

CN Alaxan

CN Algofen

CN Am-Fam 400

CN Amibufen

CN Anafen

CN Anco

CN Andran

CN Anflagen

CN Antarene

CN Antiflam

CN Apo-Ibuprofen

CN Apsifen

CN Artofen

CN Artril

CN Artril 300

CN Atril 300

CN Balkaprofen

CN Betaprofen

CN Bloom

CN Bluton

CN Brofen

CN Brufanic

CN Brufen

CN Brufen 400

CN Brufen Retard

CN Bruflam

CN Brufort

CN Buburone.

CN Burana

CN Butacortelone

CN Butylenin

CN Carol

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS 3D CONCORD

DR 58560-75-1, 139466-08-3

MF C13 H18 O2


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DIOGENES, DIPPR*, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB,
IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA,
PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2,
USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6324 REFERENCES IN FILE CA (1957 TO DATE)

184 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

6364 REFERENCES IN FILE CAPLUS (1957 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:41987

REFERENCE 2: 139:41985

REFERENCE 3: 139:41974

REFERENCE 4: 139:41818

REFERENCE 5: 139:41788

REFERENCE 6: 139:41655

REFERENCE 7: 139:41618

REFERENCE 8: 139:41298

REFERENCE 9: 139:36906

REFERENCE 10: 139:30844

L99 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 147-24-0 REGISTRY


CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl-, hydrochloride (8CI)

OTHER NAMES:

CN .beta.-Dimethylaminoethyl benzhydryl ether hydrochloride
 CN 2-(Benzhydryloxy)-N,N-dimethylethylamine hydrochloride
 CN 2-Diphenylmethoxy-N,N-dimethylethylamine hydrochloride
 CN Alledryl
 CN Allergan
 CN Allergina
 CN Allergival
 CN Amidryl
 CN Bagodryl
 CN Bax
 CN Bena
 CN Bena-Fedrin
 CN Benadril hydrochloride
 CN Benadryl
 CN Benocten
 CN Benodine
 CN Benylin
 CN Benzantin
 CN Benzhydramine hydrochloride
 CN Benzhydrol .beta.-dimethylaminoethyl ether hydrochloride
 CN Denydryl
 CN Dibondrin
 CN Difenhydramine hydrochloride
 CN Dimedrol
 CN Dimedrol hydrochloride
 CN Diphantine
 CN Diphenhydramine hydrochloride
 CN Fenyhist
 CN Halbmond
 CN Histacyl
 CN Noctomin
 CN Resmin
 CN Restamin
 CN S 8
 CN Sedopretten
 CN Sekundal D
 CN Syntedril
 CN Vena
 CN Wehydryl
 DR 8052-21-9
 MF C17 H21 N O . Cl H
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST,
 CIN, CSCHEM, DETHERM*, DIOGENES, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHARMASEARCH, PIRA, PROMT,
 RTECS*, SPECINFO, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (58-73-1)



HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1279 REFERENCES IN FILE CA (1957 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1280 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:41788
 REFERENCE 2: 139:26674
 REFERENCE 3: 139:15273
 REFERENCE 4: 139:12826
 REFERENCE 5: 138:406923
 REFERENCE 6: 138:406917
 REFERENCE 7: 138:390926
 REFERENCE 8: 138:373970
 REFERENCE 9: 138:343878
 REFERENCE 10: 138:343856

L99 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2003 ACS
 RN 58-73-1 REGISTRY
 CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl- (7CI, 8CI)
 OTHER NAMES:
 CN .alpha.- (2-Dimethylaminoethoxy)diphenylmethane
 CN .beta.-Dimethylaminoethanol diphenylmethyl ether
 CN .beta.-Dimethylaminoethylbenzhydrylether
 CN 2-(Benzhydryloxy)-N,N-dimethylethylamine
 CN 2-(Diphenylmethoxy)-N,N-dimethylethylamine
 CN Benzhydramine
 CN Dimedrol base
 CN Diphenhydramine
 CN DPH
 CN FAR 90X2
 CN N-[2-(Diphenylmethoxy)ethyl]-N,N-dimethylamine
 CN O-Benzhydryldimethylaminoethanol
 CN Probedryl
 FS 3D CONCORD
 MF C17 H21 N O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*,
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR,
 PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2,
 USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



3008 REFERENCES IN FILE CA (1957 TO DATE)
62 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3018 REFERENCES IN FILE CAPLUS (1957 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:46005

REFERENCE 2: 139:41851

REFERENCE 3: 139:41788

REFERENCE 4: 139:26674

REFERENCE 5: 139:17578

REFERENCE 6: 139:17066

REFERENCE 7: 139:6872

REFERENCE 8: 138:396066

REFERENCE 9: 138:395915

REFERENCE 10: 138:390926

=> fil wpix
FILE 'WPIX' ENTERED AT 17:26:36 ON 16 JUL 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 16 JUL 2003 <20030716/UP>
MOST RECENT DERWENT UPDATE: 200345 <200345/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> NEW WEEKLY SDI FREQUENCY AVAILABLE --> see NEWS <<<

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L129 ANSWER 1 OF 3 WPIX (C) 2003 THOMSON DERWENT
AN 2002-590698 [63] WPIX

DNC C2002-167152

TI Composition useful for treating pain-associated sleep
disturbances comprises **ibuprofen** and **diphenhydramine**.

DC B05

IN BIANCO, J; COOK, G D; COOPER, S; DOYLE, G; FORT, J J; GIAMALVA, D H; KOCH,

PA T S; BIANCO, G; COOPER, S A; DOYLE, G A
 (BIANCO-I) BIANCO J; (COOK-I) COOK G D; (COOP-I) COOPER S; (DOYL-I) DOYLE G;
 (FORT-I) FORT J J; (GIAM-I) GIAMALVA'D H; (KOCHE-I) KOCH T S; (AMHP) WYETH
 CYC 100
 PI WO 2002056877 A1 20020725 (200263)* EN 75p A61K031-00
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
 US 2002177626 A1 20021128 (200281) A61K031-19
 ADT WO 2002056877 A1 WO 2002-US3855 20020118; US 2002177626 A1 Provisional US
 2001-262387P 20010119, US 2002-46727 20020117
 PRAI US 2001-262387P 20010119; US 2002-46727 20020117
 IC ICM A61K031-00; A61K031-19
 ICS A61K031-135
 AB WO 200256877 A UPAB: 20021001
 NOVELTY - A composition comprises **ibuprofen** (I) and
diphenhydramine (II).
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for
 evaluating a compound or composition for the treatment of a
 pain-associated **sleep** disturbance in patients experiencing at
 least moderate or several levels of pain involving:
 (a) administering the compound or composition to the patient after
 oral surgery;
 (b) sending the patient to bed earlier than his usual bedtime; and
 (c) assessing the effectiveness of the compound or the composition.
 ACTIVITY - Analgesic; Sedative.
 Patients suffering from pain associated **sleep** disturbances
 were administered **ibuprofen** (400 mg) and **diphenhydramine**
 (50 mg) in a single soft gelatin **capsule** before bedtime. The
 symptoms of their pain associated **sleep** disturbances improved.
 They slept for a longer duration and also fell asleep faster than
 expected. Thus the composition was useful for treating pain associated
sleep disturbances.
 MECHANISM OF ACTION - None given.
 USE - For treating pain-associated **sleep** disturbances
 affecting **sleep** duration (claimed) (preferably shortened
sleep duration). The pain-associated **sleep** disturbances
 include difficulties in falling asleep and staying asleep.
 ADVANTAGE - The composition does not have negative interactions
 between (I) and (II) during formulation or when placed on shelves. The
 composition is stable chemically and physically. The combination of (I)
 and (II) yields a salient effect greater than that of (II) alone. (I)
 Alone is effective for only 4-6 hours while the composition is effective
 for longer periods of time.
 Dwg.0/29
 FS CPI
 FA AB; DCN
 MC CPI: B10-B03B; B10-C02; B10-C04C; B11-C08; B12-K04; **B12-M11B;**
 B12-M11C; B12-M11K; B14-C01; B14-J01B1
 TECH UPTX: 20021001
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The
 composition comprises (I) (50-800, preferably 200 mg) and (II) in the form
 of **diphenhydramine HCl** (12.5-50, preferably 25 mg) or
diphenhydramine citrate (19-38, preferably 38 mg).
 Preferred Method: The step (c) is performed by evaluating at least one of
sleep latency, sum of pain relief and pain intensity differences
 over 0-3 hours (SPRID3), cumulative percent asleep at 60 minutes, ease of
 falling asleep, duration of **sleep**, global evaluation of
sleep, median time to rescue medication, percent of patients
 requiring rescue medication, global assessment as a pain reliever, global

assessment as a **sleep** acid or pain relief intensity difference (PRID) 90 or 60 minutes (preferably **sleep** latency, **sleep** duration and SPRID3). The patient is sent to bed 1-6 (preferably at least 1, 3 or upto 6) hours earlier than his usual bedtime.

ABEX UPTX: 20021001

ADMINISTRATION - Administration of (I) is 50-800 (preferably 200) mg. The dosage for **diphenhydramine HCl** is 12.5-50 (preferably 25) mg and that for **diphenhydramine citrate** is 19-38 (preferably 38) mg. The composition is a bilayer **tablet** or **caplet** or a soft gelatin **capsule** containing **polyethylene glycol** and is administered in one or two doses concomitantly. The second dose is optionally administered (all claimed). The composition is administered from 90 minutes before bedtime to immediately before bedtime (preferably 45-15 minutes especially 30 minutes before bedtime).

EXAMPLE - **Diphenhydramine hydrochloride** (40.050 kg) was dissolved in water (46.138 kg) and **polyethylene glycol** (molecular weight 600) (200.250 kg) was added to it. **Polyethylene glycol** (molecular weight 600) (326.808 kg) was also added to **ibuprofen** (320.400 kg) and mixed. Potassium hydroxide (41.011 kg) was dissolved in water (34.603 kg) and added to the **ibuprofen** dispersion and mixed under vacuum. The temperature was maintained at 75-125 degrees F. The **diphenhydramine hydrochloride** solution was added to the **ibuprofen** /potassium hydroxide/**polyethylene glycol** solution and mixed under vacuum. The solution was deaerated under vacuum for at least 15 minutes and pressurized. The solution was **encapsulated** with in a gelatin shell and processed to completion. The **capsule** had the following composition (mg): **ibuprofen** (200), **diphenhydramine HCl** (25), DandC Red No. 33 (RTM) (0.0113), FDandC Blue No.1 (RTM) (0.0170), **polyethylene glycol** (molecular weight 600) (329), potassium hydroxide (25.6), purified water (50.4), ANDRISORB 85/70 (RTM) (93.4) and gelatin (164).

L129 ANSWER 2 OF 3 WPIX (C) 2003 THOMSON DERWENT

AN 2001-290269 [30] WPIX

DNC C2001-088857

TI Liquid softgel fill formulations comprising high concentrations of **ibuprofen** in free form, and **capsules** containing them.

DC A14 A25 A96 B05 B07

IN GULLAPALLI, R P

PA (BANN-N) BANNER PHARMACAPS INC

CYC 95

PI WO 2001015688 A1 20010308 (200130)* EN 20p A61K031-19

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2000070949 A 20010326 (200137) A61K031-19

US 6251426 B1 20010626 (200138) A61K009-48 <--

EP 1207872 A1 20020529 (200243) EN A61K031-19

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

JP 2003508434 W 20030304 (200319) 21p A61K031-192

ADT WO 2001015688 A1 WO 2000-US23908 20000901; AU 2000070949 A AU 2000-70949 20000901; US 6251426 B1 US 1999-389003 19990902; EP 1207872 A1 EP 2000-959667 20000901, WO 2000-US23908 20000901; JP 2003508434 W WO 2000-US23908 20000901, JP 2001-519902 20000901

FDT AU 2000070949 A Based on WO 200115688; EP 1207872 A1 Based on WO 200115688; JP 2003508434 W Based on WO 200115688

PRAI US 1999-389003 19990902
 IC ICM A61K009-48; A61K031-19; A61K031-192
 ICS A61K009-06; A61K009-58; A61K009-64;
 A61K009-66; A61K045-00; A61K047-14; A61K047-22; A61K047-32;
 A61K047-34; A61P029-00
 AB WO 200115688 A UPAB: 20010603
 NOVELTY - Stable liquid softgel fill formulations comprising high concentrations of **ibuprofen** in free form, **polyethylene glycol** and polyvinylpyrrolidone, and soft gelatin **capsules** containing them, are new.
 DETAILED DESCRIPTION - A liquid softgel fill formulation comprises (as wt.%):
 (a) greater than 30% **ibuprofen** (I) in free acid form in solution;
 (b) 30-60% **polyethylene glycol** (PEG);
 (c) 10-30% polyvinylpyrrolidone (PVP); and
 (d) optionally 1-10% surfactant to increase bioavailability of (I).
 INDEPENDENT CLAIMS are included for softgel **capsules** comprising a sheath enclosing a liquid fill as described above.
 USE - For administration of **ibuprofen**.
 ADVANTAGE - Use of a large amount of PVP permits a reduction in the amount of PEG required, reducing the esterification reaction between (I) and PEG.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: A03-C01; A04-D05A; A05-H04; A12-V01; B04-C03C; B10-C04C; B12-M07;
B12-M11C
 TECH UPTX: 20010603
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition preferably comprises at least 35 wt.% (I); 30-50% PEG having average molecular weight (MW) 200-1,000; and 15-30% PVP having MW 2,000-54,000. The surfactant is e.g. an ester of d-alpha-tocopheryl, a **polyoxyethylene** castor oil derivative, or polyglycolized glyceride. The composition may further comprise up to 6% of a nasal decongestant (e.g. pseudoephedrine hydrochloride), or up to 10% of an antihistaminic (e.g. **diphenhydramine hydrochloride**). The sheath of the softgel **capsule** comprises 45-75% gelatin; 20-40% plasticizer (e.g. sorbitol, sorbitol special, and/or maltitol); and 5-15% water. The total weight of the **capsule** fill is less than 600 mg, and the weight of (I) is at least 200 mg.
 ABEX UPTX: 20010603
 EXAMPLE - A fill formulation was prepared comprising (as wt.%): (I) 35%; PEG 600 37%; Kollidon17 PF (RTM: PVP, MW 10,000) 22%; and Vitamin E TPGS 6%.
 L129 ANSWER 3 OF 3 WPIX (C) 2003 THOMSON DERWENT
 AN 1997-369376 [34] WPIX
 DNC C1997-118673
 TI Cold remedy soft **capsule** - comprises solution of **ibuprofen** and second drug e.g. histamine antagonist.
 DC A96 B05
 PA (RPSE-N) RP SEALER KK; (SATO) SATO SEIYAKU KK
 CYC 1
 PI JP 09157162 A 19970617 (199734)* 12p A61K031-19
 JP 3382076 B2 20030304 (200319) 10p A61K031-19
 ADT JP 09157162 A JP 1995-322706 19951212; JP 3382076 B2 JP 1995-322706 19951212
 FDT JP 3382076 B2 Previous Publ. JP 09157162
 PRAI JP 1995-322706 19951212
 IC ICM A61K031-19
 ICS A61K009-08; A61K009-48; A61K031-52; A61K045-00;

A61K045-06; A61K047-14; A61K047-34; A61P011-10; A61P011-14;
 A61P025-02; A61P025-04; A61P025-20; A61P025-26; A61P029-00;
 A61P043-00

ICI A61K031-19, A61K045:06

AB JP 09157162 A UPAB: 19970820

A cold remedy soft **capsule** comprises a soln. of **ibuprofen** and one or more second drugs from histamine antagonist, antitussive agent, expectorant, sympathetic nerve stimulant and central stimulant in a base contg. a surfactant from **polyoxyethylene** (POE) sorbitan fatty acid ester, POE hardened castor oil and polyglycerol fatty acid ester and water, and no hydroxide ions.

The central stimulant is anhydrous caffeine, caffeine or sodium benzoate caffeine.

The surfactant has HLB of 13-18.

POE (20) sorbitan monooleate (1030.5g) at about 60 deg.C was added with **ibuprofen** (225g), **diphenhydramine hydrochloride** (37.5g), dihydrocodeine phosphate (12b), noscapine hydrochloride (24mg), dl-methylephedrine hydrochloride (30g), guaifenesin (125g) and anhydrous caffeine (15g). The mixt. was vigorously stirred using a homogenizer, cooled to about 40 deg.C, added with purified water (106g), deaerated under vacuum and filtered through a 100 mesh. The filtrate (each 535mg) was filled in a gelatin film [comprising gelatin (100g) and glycerol (30g)] to give 3,000 soft **capsules**.

ADVANTAGE - Absorption of the drugs is excellent, **ibuprofen** is stable in the **capsule**, and the **capsule** need not be measured and is handy to carry.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: A10-E07; A12-V01; B04-A04; B04-A06; B04-A10; B04-N02; B05-A01B;
 B10-B03B; B10-C04C; B12-M09; **B12-M11C**; B14-C04; B14-L09

=> d his

(FILE 'HOME' ENTERED AT 16:42:01 ON 16 JUL 2003)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 16:42:20 ON 16 JUL 2003
 L1 1 S US20020177626/PN

FILE 'HCAPLUS' ENTERED AT 16:42:57 ON 16 JUL 2003
 S 15687-27-1/REG#

FILE 'REGISTRY' ENTERED AT 16:42:57 ON 16 JUL 2003

FILE 'HCAPLUS' ENTERED AT 16:42:57 ON 16 JUL 2003
 S 58-73-1/REG#

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 16 JUL 2003

FILE 'HCAPLUS' ENTERED AT 16:42:58 ON 16 JUL 2003

FILE 'REGISTRY' ENTERED AT 16:43:10 ON 16 JUL 2003

L2	1 S 15687-27-1
L3	1 S 58-73-1
L4	1 S 25322-68-3
L5	137 S C13H18O2/MF AND 46.150.18/RID AND BENZENEACETIC
L6	3 S L5 AND IBUPROFEN
L7	3 S L2,L6
L8	209 S 58-73-1/CRN SEL RN L7
L9	313 S E1-E3/CRN

L10 4 S L8 AND L9
 L11 1 S L10 AND 2/NC
 L12 110 S L8 NOT (MXS OR IDS OR PMS)/CI
 L13 29 S L12 NOT (UNSPECIFIED OR COMPD OR WITH)
 L14 26 S L13 NOT SALT
 L15 23 S L14 NOT (CONJUGATE OR CR/ELS)
 L16 3 S L13 NOT L14
 L17 26 S L15,L16
 L18 1 S L17 AND CLH
 L19 2 S L17 AND C6H8O7
 L20 3 S L18,L19
 L21 23 S L17 NOT L20
 L22 44 S L9 NOT ((MXS OR IDS OR PMS)/CI OR UNSPECIFIED OR COMPD OR WI
 L23 41 S L22 NOT (LYSINE OR CYCLODEXTRIN OR TETRAKIS)

FILE 'HCAPLUS' ENTERED AT 16:51:26 ON 16 JUL 2003

L24 1 S L11
 L25 6751 S L7 OR L23
 L26 7215 S IBUPROFEN
 L27 27 S DEXIBUPROFEN
 L28 140 S 2 4 ISOBUTYLPHENYL PROPIONIC ACID
 L29 39 S 2 P ISOBUTYLPHENYL PROPIONIC ACID
 L30 8206 S L25-L29
 L31 1294 S L20 OR L21
 L32 4208 S DIPHENHYDRAMINE
 L33 16 S DIPHENHYDRAMINE CITRATE
 L34 527 S DIPHENHYDRAMINE HYDROCHLORIDE
 L35 459 S DIPHENHYDRAMINE(A) HCL
 L36 535 S DIMEDROL
 L37 5035 S L31-L36
 L38 227 S L30 AND L37
 L39 33 S L38 AND L4
 L40 33 S L38 AND (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR PO
 L41 0 S L38 AND POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE())
 L42 40 S L39,L40
 L43 23 S L38 AND POLYOXYALKYLENE
 L44 42 S L42,L43
 L45 1 S L44 AND SLEEP?
 E SLEEP/CT
 L46 7983 S E3-E10
 E E3+ALL
 L47 8142 S E2+NT
 L48 1580 S E3,E4/BI
 L49 1 S L44 AND L46-L48
 L50 1 S L38 AND L46-L48
 L51 1 S L38 AND SLEEP?
 E INSOMNIA/CT
 L52 570 S E3,E4
 E E3+ALL
 L53 0 S L38 AND L52
 L54 0 S L38 AND INSOMN?
 L55 1 S L49-L51
 L56 3046 S L3
 L57 197 S L56 AND L30
 L58 1 S L57 AND SLEEP?
 L59 0 S L57 AND INSOMN?
 L60 1 S L57 AND L46-L48
 L61 1 S L55,L58,L60
 L62 257 S L38,L57
 L63 19 S L62 AND PAIN?
 L64 76 S L62 AND ANALGE?
 E PAIN/CT
 E E3+ALL

L65 86 S L62 AND (E3+NT OR E5+NT OR E6+NT OR E7+NT OR E8+NT OR E9+NT O
 L66 98 S L63-L65
 L67 229 S L62 AND (PD<=20010119 OR PRD<=20010119 OR AD<=20010119)
 L68 87 S L67 AND L66
 L69 28 S L67 AND L4
 L70 27 S L67 AND (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR PO
 L71 0 S L67 AND POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE())
 L72 15 S L67 AND POLYOXYALKYLENE
 L73 34 S L69-L72
 E COOPER S/AU
 L74 116 S E3,E4
 E COOPER STEVE/AU
 L75 5 S E3,E5
 E COOPER STEPHEN/AU
 L76 88 S E3-E5
 E COOK G/AU
 L77 41 S E3,E8,E9
 E COOK GRAHAM/AU
 L78 9 S E3-E5
 E KOCH T/AU
 L79 73 S E3,E10
 E KOCH TODD/AU
 L80 3 S E4,E5
 E GIAMALVA D/AU
 L81 26 S E3-E6
 E BIANCO J/AU
 L82 21 S E3-E7
 L83 1 S E19
 E FORT J/AU
 L84 52 S E3,E8-E11
 E DOYLE G/AU
 L85 59 S E3-E11
 L86 7 S E38-E40
 L87 1 S L74-L86 AND L62
 L88 2 S WYETH?/PA,CS AND L62
 L89 2 S L61,L87,L88
 L90 1 S L73 AND L89
 L91 2 S L89,L90
 L92 3 S L24,L91
 L93 33 S L73 NOT L92
 L94 11 S L93 AND (?CAPSUL? OR ?CAPLET? OR ?TABLET?)
 L95 22 S L93 NOT L94
 SEL DN AN 7
 L96 1 S L95 AND E1-E3
 SEL DN AN L94 2
 L97 1 S L94 AND E4-E6
 L98 5 S L92,L96,L97

FILE 'HCAPLUS' ENTERED AT 17:09:43 ON 16 JUL 2003
 SEL HIT RN L98

FILE 'REGISTRY' ENTERED AT 17:09:58 ON 16 JUL 2003
 L99 6 S E7-E12

FILE 'WPIX' ENTERED AT 17:10:07 ON 16 JUL 2003
 L100 1751 S L26/BIX OR L27/BIX OR L28/BIX OR L29/BIX
 E IBUPROFEN/DCN
 E E3+ALL
 L101 1701 S E2 OR 1987/DRN
 L102 3 S E4
 L103 556 S E8
 L104 15 S E10
 L105 5 S E14

L106 33 S E20
L107 2279 S L100-L106
L108 496 S L32/BIX OR L33/BIX OR L34/BIX OR L35/BIX OR L36/BIX
E DIPHENHYDRAMINE/DCN
E E3+ALL
L109 501 S E2 OR 0170/DRN
L110 164 S E4
L111 139 S L107 AND L108-L110
E R02044+ALL/DCN
L112 7674 S E1 OR 2044/DRN
L113 47628 S (PEG OR POLYETHYLENEGLYCOL OR POLYETHYLENEOXIDE OR POLYOXYETH
L114 2062 S (POLY() (ETHYLENEGLYCOL OR ETHYLENEOXIDE OR ETHYLENE) () (GLYCOL
L115 32310 S (POLYETHYLENE() (GLYCOL OR OXIDE) OR POLYOXY ETHYLENE OR POLY
L116 35 S L111 AND L112-L115
L117 16 S L116 AND (?CAPSUL? OR ?CAPLET? OR ?TABLET?) /BIX
L118 10 S L116 AND (R031 OR R033 OR R034 OR R038) /M0,M1,M2,M3,M4,M5,M6
L119 14 S L116 AND (B12-M11 OR B12-M11A OR B12-M11B OR B12-M11C OR B12-
L120 0 S L116 AND (C12-M11 OR C12-M11A OR C12-M11B OR C12-M11C OR C12-
L121 17 S L117-L119
L122 18 S L116 NOT L121
L123 27 S L116 AND A61K009/IC, ICM, ICS, ICA, ICI
L124 15 S L123 AND L121
L125 17 S L121, L124
L126 12 S L123 NOT L125
L127 1 S L125 AND SLEEP?/BIX
L128 17 S L125, L127 AND M782/M0,M1,M2,M3,M4,M5,M6
SEL DN AN 5 8 11
L129 3 S L128 AND E1-E6

FILE 'WPIX' ENTERED AT 17:26:36 ON 16 JUL 2003